RESEARCH AGREEMENTResearch Agreement • October 31st, 2014 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • New Jersey
This Research Agreement (the “Agreement”), effective as of June 18th, 2012 (“Effective Date”), is entered into by and between Enumeral Biomedical Corp., a Delaware corporation with an address at 1450 Broadway, 24th Floor, New York, New York 10018 ("ENUMERAL"), and sanofi-aventis U.S. Inc., having an address at 1041 Route 202-206, P.O. Box 6800, Bridgewater, NJ 08807-0800 (hereinafter referred to as “SANOFI US”). Each of ENUMERAL and SANOFI US are referred to herein as a “Party” or collectively as the “Parties”.
MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND ENUMERAL BIOMEDICAL CORP EXCLUSIVE PATENT LICENSE AGREEMENTPatent License Agreement • October 31st, 2014 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute of Technology ("M.I.T."), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Enumeral Biomedical Corp., Inc. ("COMPANY"), a Delaware corporation, with a principal place of business at 1450 Broadway, 24th Floor, New York, NY 10018.
CONTRACT RESEARCH AGREEMENTContract Research Agreement • October 31st, 2014 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations
Crucell Holland B.V., a private company with limited liability, with offices located at Archimedesweg 4, 2333 CN Leiden, the Netherlands, (“Crucell”),
Portions of this document have been redacted pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended. Redacted portions are...Master Service Provider Agreement • October 31st, 2014 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • New Jersey
THIS AGREEMENT (the “Agreement”) is made as of the 14th day of March, 2012 (“Effective Date”), by and between Anthrogenesis Corporation, a New Jersey Corporation, doing business as Celgene Cellular Therapeutics (a wholly owned subsidiary of Celgene Corporation) having its principal place of business at 33 Technology Drive, 2nd Floor, Warren, NJ 07059 (together with its affiliates hereinafter collectively referred to as “CCT”) and Enumeral Biomedical Corporation, having a place of business at 1450 Broadway, 24th Floor, New York, NY 10018 (hereinafter called “Service Provider”).
FIRST AMENDMENTFirst Amendment • October 31st, 2014 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations
This First Amendment, effective as of the date set forth above the signatures of the parties below, amends the Exclusive Patent License Agreement dated April 15, 2011 (the “LICENSE AGREEMENT”) between the Massachusetts Institute of Technology, a Massachusetts corporation having its principal office at 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“M.I.T.”), and Enumeral Biomedical Corp., a Delaware corporation having its principal place of business at 1450 Broadway, 24th Floor, New York, NY 10018 (“COMPANY”).
SERVICES AGREEMENTServices Agreement • October 31st, 2014 • Enumeral Biomedical Holdings, Inc. • Pharmaceutical preparations • New York
This Services Agreement (“Agreement”) is entered into as of the 8th day of October 2013 (“Effective Date”) between Novartis Pharma AG located at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Enumeral Biomedical Corporation (a Delaware Company), located at 1450 Broadway 24th floor, New York, NY, 10018 (“Enumeral”), each individually a “Party” or collectively “Parties” to this Agreement.
